Journal of Renal and Hepatic Disorders http://jrenhep.com/index.php/jrenhep <p><img style="padding-right: 15px; padding-bottom: 15px; float: left;" src="/public/site/images/jdisord/Jrenhep_logo_png_1001.png">Journal of Renal and Hepatic Disorders is a peer-reviewed, online-only, open access journal that publishes basic science and clinical research articles on disorders of the kidneys and the liver. In addition to considering disorders of each organ separately, the journal aims to be a scholarly forum for discussing how disorders of one organ influence the other. Chronic liver disease is associated with primary and secondary kidney diseases. Similarly, renal disorders are associated with hepatic disorders. Original articles, reviews and case reports on any aspects of kidneys and liver are suitable for submission.</p> en-US <p>Authors who publish with this journal agree to the following terms:</p><ul><li>Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a <a title="License" href="http://creativecommons.org/licenses/by/4.0/" target="_blank">Creative Commons Attribution License</a> that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.</li><li>Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.</li></ul>Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See <a href="http://opcit.eprints.org/oacitation-biblio.html" target="_new">The Effect of Open Access</a> editor@jrenhep.com (Managing Editor) editor@jrenhep.com (Managing Editor) Sat, 30 Jun 2018 08:25:22 -0700 OJS 3.1.1.4 http://blogs.law.harvard.edu/tech/rss 60 Potassium Profiling in Hemodialysis http://jrenhep.com/index.php/jrenhep/article/view/34 Cardiac dysrhythmia and sudden death account for a large proportion of cardiac mortality in dialysis patients. Risk factors for sudden death that are specific to dialysis patients include fluid and electrolyte imbalances during hemodialysis, particularly those of potassium. The risk of arrhythmia may be related to changes in serum K+ concentration during dialysis, and thus close attention should be paid to the dialysate K+ concentration and the serum–dialysate concentration gradient. Potassium profiling is a technique where the dialysate K+ concentration is gradually reduced to keep the gradient between blood and dialysate at a non-fluctuating low level. We provide a review of studies that compare constant potassium concentration in dialysate to gradual reduction in dialysate potassium concentration. These studies illustrate that adequate and more gradual potassium removal can be achieved with potassium profiling techniques, while having lower cardiac irritability. Nikhil Agrawal, Sahil Agrawal, Nishita Tripathi, Mark Segal ##submission.copyrightStatement## http://creativecommons.org/licenses/by/4.0 http://jrenhep.com/index.php/jrenhep/article/view/34 Tue, 07 Aug 2018 03:27:30 -0700 Monitoring the Effects of Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Switch for Tubulotoxicity in Highly Treatment-Experienced or in Very Sick Individuals Infected with HIV http://jrenhep.com/index.php/jrenhep/article/view/33 <p>Tenofovir disoproxil fumarate (TDF) is a common antiretroviral utilised in the treatment of human immunodeficiency virus (HIV) and hepatitis B infections. It is associated with the development of tubulotoxicity and tubulopathies, and is not recommended in the treatment of patients with baseline chronic kidney disease. Until now, guidelines have suggested frequent monitoring of serum biochemistry to detect the development of such complications. In recent trials, a new prodrug formulation of tenofovir alafenamide (TAF) has been shown to exhibit less tubular toxicity than its counterpart due to a lower serum concentration of its metabolites. In this article, we share our experience with two patients who developed tubulotoxicity following the commencement of TDF-based regimens in HIV, and its improvement following its change to TAF, and review the available literature regarding tenofovir-based nephrotoxicity.</p> Nicole Marie Lioufas, Alan Street, Paul Champion de Crespigny, Stephen G Holt ##submission.copyrightStatement## http://creativecommons.org/licenses/by/4.0 http://jrenhep.com/index.php/jrenhep/article/view/33 Sat, 30 Jun 2018 08:25:22 -0700